Molecular Markers of Chemotherapy Toxicity in Colorectal Cancer

被引：2
|
作者：
Braun, Michael S. [1 ]
Seymour, Matthew T. [1 ]
机构：
[1] Univ Leeds, Leeds Inst Mol Med, Sect Oncol & Clin Res, Leeds, W Yorkshire, England
来源：
CURRENT COLORECTAL CANCER REPORTS | 2011年 / 7卷 / 01期
关键词：
Fluorouracil; Irinotecan; Oxaliplatin; Pharmacogenomics; Toxicity; Colorectal;
D O I：
10.1007/s11888-010-0078-6
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
Personalized medicine appears to be the inevitable consequence of improvements in our understanding of the mechanisms of action of chemotherapeutic agents, as well as the description of the human genome and its impact on our understanding of the genes involved in DNA repair and drug metabolism. These rapid developments have been associated with the first efforts to establish genetic predictors of chemotherapy efficacy and toxicity for the chemotherapy drugs active in colorectal cancer-fluorouracil, irinotecan, and oxaliplatin.
引用
收藏
页码：105 / 111
页数：7
相关论文
共 50 条
  • [41] Molecular predictive factors for toxicity in colorectal cancer patients
    Tonini, G
    Vincenzi, B
    Perrone, G
    La Cesa, A
    Grilli, C
    Virzi, V
    Gasparro, S
    Leoni, V
    Rabitti, C
    Santini, D
    JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (16) : 297S - 297S
  • [42] CURRENT STATUS OF ADJUVANT CHEMOTHERAPY FOR COLORECTAL-CANCER - CAN MOLECULAR MARKERS PLAY A ROLE IN PREDICTING PROGNOSIS
    OCONNELL, MJ
    SCHAID, DJ
    GANJU, V
    CUNNINGHAM, J
    KOVACH, JS
    THIBODEAU, SN
    CANCER, 1992, 70 (06) : 1732 - 1739
  • [43] Analysis of toxicity and efficacy of chemotherapy in elderly patients with advanced colorectal cancer
    Simoni, C
    Chiara, S
    Nobile, MT
    Vincenti, M
    Gozza, A
    Barzacchi, M
    Sanguineti, O
    Rosso, R
    ANNALS OF ONCOLOGY, 1998, 9 : 82 - 82
  • [44] Efficacy and Toxicity of Addition of Bevacizumab to Chemotherapy in Patients with Metastatic Colorectal Cancer
    Ruan, Wen-Cong
    Che, Yue-Ping
    Ding, Li
    Li, Hai-Feng
    COMBINATORIAL CHEMISTRY & HIGH THROUGHPUT SCREENING, 2018, 21 (10) : 718 - 724
  • [45] Plasma biomarkers for early prediction of chemotherapy response and toxicity in colorectal cancer
    Chua, W.
    Randall, S.
    McKay, M. J.
    Horvath, L.
    Clarke, S. J.
    Molloy, M. P.
    EJC SUPPLEMENTS, 2009, 7 (02): : 112 - 112
  • [46] Risk Assessment in Early Colorectal Cancer: Histological and Molecular Markers
    Resch, Annika
    Langner, Cord
    DIGESTIVE DISEASES, 2015, 33 (01) : 77 - 85
  • [47] Statistical correlation between some molecular markers in colorectal cancer
    Vrabie, Camelia Doina
    Ceausu, Mihai
    Petrescu, Angela
    Waller, Maria
    VIRCHOWS ARCHIV, 2007, 451 (02) : 220 - 220
  • [48] Palliative therapy of colorectal cancer - stratification for molecular markers - trials
    Wicki, A.
    ONCOLOGY RESEARCH AND TREATMENT, 2019, 42 : 166 - 166
  • [49] Possible molecular markers for efficacy of cetuximab in metastatic colorectal cancer
    Nature Clinical Practice Oncology, 2005, 2 (8): : 381 - 381
  • [50] Epithelial molecular markers in the peripheral blood of patients with colorectal cancer
    Khair, Ghaith
    Monson, John R. T.
    Greenman, John
    DISEASES OF THE COLON & RECTUM, 2007, 50 (08) : 1188 - 1203
12345